Products for license
We have launched several biosimilar products by leveraging our strong pipeline to help increase healthcare accessibility.
Why are biosimilars in demand?
Biosimilars have no clinical differentiation from existing, approved biologics, with equivalent efficacy and safety. Product demand is increasing because of:
- Patent expirations: The expiration of patents for many blockbuster biologics has paved the way for biosimilar manufacturers to develop and commercialize these products
- Cost-effectiveness: Healthcare systems worldwide are facing increasing pressure to control costs. Biosimilars offer a more affordable alternative to biologics while maintaining comparable efficacy and safety. This cost-effectiveness makes biosimilars an attractive option for healthcare payers and providers
- Technological advancements: Advancements in biotechnology have enabled the development of biosimilars that are highly similar to their originator products. This has addressed concerns about immunogenicity and other potential risks associated with biosimilars
- Regulatory support: Regulatory agencies worldwide have played a significant role in supporting the development and approval of biosimilars. Establishing clear regulatory pathways and guidelines has facilitated the timely and efficient evaluation of biosimilar applications
Our biosimilars products
The development and manufacture of biosimilars is a complex and challenging process.
We have invested in our biosimilar capabilities with our advanced pipeline and EnzeneXTM continuous bioprocess manufacturing, allowing us to develop, manufacture and launch a range of biosimilar products.
Wave I product pipeline
| Originator | Disease Indication | Treatments | India Launch Year | Global Launch year |
| Teriparatide (Forteo®) | Osteoporosis | A recombinant human parathyroid hormone that acts as an anti-osteoporosis agent. Used to treat postmenopausal women and to increase bone mass in men with osteoporosis. Also used to treat men and women with osteoporosis associated with sustained systemic glucocorticoid therapy at high risk for fracture. | 2021 | Expected 2025 |
| Denosumab (Prolia®) | Postmenopausal osteoporosis | A human IgG2 monoclonal antibody (mAb) used to treat postmenopausal osteoporosis, fractures and bone loss in patients undergoing hormone ablation for cancer, as well as inhibition of the progression of bone erosion associated with rheumatoid arthritis. | 2021 | Expected 2025 |
| Denosumab (Xgeva®) | Giant cell tumor of bone | A human IgG2 mAb that acts as an antineoplastic agent for the prevention of skeletal-related events in patients with bone metastases from multiple myeloma and giant cell tumor of bone. | NA | Expected 2026 |
| Romiplostim (Nplate®) | Immune thrombocytopenic purpura (ITP) | An Fc-peptide fusion protein for treating adults and pediatrics (1+) with long-term ITP, and for treating aplastic anemia (AA) in adults with inadequate response to conventional therapy. | 2021 | Expected 2026 |
| Adalimumab (Humira®) | Rheumatoid arthritis | A human IgG1 mAb for human tumor necrosis factor (TNF). Used to reduce signs and symptoms, inhibiting the progression of structural damage and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. | 2023 | NA |
| Cetuximab (Erbitux®) | Squamous cell cancer of the head and neck | A chimeric igG1 mAb that acts as an anti-neoplastic agent for treating patients with epidermal growth factor receptor (EGPR)-expressing, RAS wild-type metastatic colorectal cancer and for the treatment of patients with squamous cell cancer of the head and neck. | 2023 | NA |
| Bevacizumab (Avastin®) | Metastatic colorectal cancer | A recombinant humanized IgG1 mAb used to treat metastatic colorectal cancer, non-squamous non-small cell lung cancer and glioblastoma. | 2023 | NA |
| Ranibizumab (Lucentis®) | Neovascular (Wet) age-related macular degeneration | A humanized mAb fragment and a recombinant humanized igG1 isotype designed to bind and inhibit vascular endothelial growth factor (VEGF-A). Used for treating neovascular (Wet) age-related macular degeneration, macular edema following retinal vein occlusion (RVO), and diabetic macular edema. | 2023 | NA |
| Pertuzumab (Perjeta®) | HER2-positive metastatic breast cancer | An anti-neoplastic agent used in combination with trastuzumab and docetaxel in adults with HER2-positive metastatic or locally recurrent unresectable breast cancer who have not received previous anti-HER2 therapy or chemotherapy. Also used in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adults with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer with high risk or recurrence. | Expected 2025 | NA |
Partners we work with
Biomm
Centurion
IDD biotech
Ipca
Lupin
Mankind pharma
Pharmasyntez
Shin Poong Pharm
SSB-Sartorius
Theramex
Start your biosimilars journey
Find out more about our biosimilars products and see how we can help you deliver trusted and affordable medicines at speed.